Raia Drogasil (OTCMKTS:RADLY – Get Free Report) is anticipated to post its results after the market closes on Tuesday, August 4th. Analysts expect Raia Drogasil to announce earnings of $0.0471 per share and revenue of $2.3188 billion for the quarter.
Raia Drogasil Price Performance
OTCMKTS:RADLY remained flat at $3.87 during trading hours on Tuesday. 6,070 shares of the company traded hands, compared to its average volume of 56,822. The company’s 50 day simple moving average is $3.56 and its 200-day simple moving average is $4.27. Raia Drogasil has a twelve month low of $2.33 and a twelve month high of $5.34.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised shares of Raia Drogasil to a “hold” rating in a research note on Thursday, April 9th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.
Raia Drogasil Company Profile
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
Featured Stories
- Five stocks we like better than Raia Drogasil
- 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks
- 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest?
- Middleby Is Betting a Leaner Business Can Unlock More Value
- 3 Value ETFs to Consider as Growth Stocks Lag Behind
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
